Zevra Therapeutics, Inc. (ZVRA)

Zevra Therapeutics Stock Forecast

Stock Price Forecast

The 7 analysts with 12-month price forecasts for Zevra Therapeutics stock have an average target of 22.29, with a low estimate of 18 and a high estimate of 25. The average target predicts an increase of 194.45% from the current stock price of 7.57.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$18	$22.29	$22	$25
Change	+137.78%	+194.45%	+190.62%	+230.25%

Analyst Ratings

The average analyst rating for Zevra Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Oct '24	Nov '24	Dec '24	Jan '25	Feb '25	Mar '25
Strong Buy	4	4	4	4	4	5
Buy	3	3	3	3	3	3
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	7	7	7	7	7	8

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Sumant Kulkarni Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $23 → $25	Strong Buy	Maintains	$23 → $25	+230.25%	Mar 13, 2025
Eddie Hickman Guggenheim	Guggenheim	Strong Buy Maintains $20 → $22	Strong Buy	Maintains	$20 → $22	+190.62%	Mar 13, 2025
Oren Livnat HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $20	Strong Buy	Reiterates	$20	+164.20%	Mar 13, 2025
Jason Butler Citizens Capital Markets	Citizens Capital Markets	Buy Maintains $17 → $18	Buy	Maintains	$17 → $18	+137.78%	Mar 12, 2025
Kristen Kluska Cantor Fitzgerald	Cantor Fitzgerald	Buy Reiterates $25	Buy	Reiterates	$25	+230.25%	Mar 12, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

89.99M

Increased by 281.10%

from 23.61M

Revenue Next Year

178.15M

Increased by 97.98%

from 89.99M

EPS This Year

0.07

from -2.28

EPS Next Year

0.64

Increased by 838.34%

from 0.07

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	13.29M	28.65M	10.16M	27.46M	23.61M	89.99M	178.15M	275.53M
Revenue Growth	3.50%	115.61%	-64.53%	170.26%	-14.02%	281.10%	97.98%	54.66%
EPS	-3.21	-2.11	-0.78	-1.30	-2.28	0.07	0.64	1.90
EPS Growth	-	-	-	-	-	-	838.34%	195.87%
Forward PE	-	-	-	-	-	110.54	11.78	3.98
No. Analysts	-	-	-	-	-	10	9	8

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	110.2M	222.6M	357.0M
Avg	90.0M	178.2M	275.5M
Low	58.5M	145.3M	225.8M

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	366.7%	147.4%	100.4%
Avg	281.1%	98.0%	54.7%
Low	147.8%	61.5%	26.7%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	1.73	1.30	2.99
Avg	0.07	0.64	1.90
Low	-0.97	-0.04	1.29

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	-	1,801.2%	365.7%
Avg	-	838.3%	195.9%
Low	-	-	101.3%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.